Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer.
A novel tissue-specific shRNA delivery system has been developed using cre-lox technology. Conditionally silenced pSico vector containing oligonucleotides of CD44shRNA and tissue-specific promoter-driven Cre-recombinase expression vector are packaged into transferrin-coated nanoparticles that can deliver shRNA into specific tumors. This system has strong potential in cancer therapy.
Ghatak
Shilenath
S
Department of Cell Biology and Anatomy, MUSC, Charleston, South Carolina 29425, USA. ghatak@musc.edu
Hascall
Viacent C
VC
Berger
Franklin G
FG
Penas
Maria M O
MM
Davis
Celestia
C
Jabari
Esmaiel
E
He
Xuezhong
X
Norris
James S
JS
Dang
Yujing
Y
Markwald
Roger R
RR
Misra
Suniti
S
D000818:Animals; D001943:Breast Neoplasms / Q000378:metabolism / Q000628:therapy; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000378:metabolism / Q000628:therapy; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics* / Q000378:metabolism; D006820:Hyaluronic Acid / Q000378:metabolism*; D019426:Integrases / Q000378:metabolism; D008297:Male; D053758:Nanoparticles; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics*; D014162:Transfection
D018960:Hyaluronan Receptors; D034741:RNA, Small Interfering; D006820:Hyaluronic Acid; C045073:Cre recombinase; D019426:Integrases